NasdaqCM - Nasdaq Real Time Price • USD
Xenetic Biosciences, Inc. (XBIO)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:25 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.79 | -0.83 | -3.43 | -0.82 |
| Low Estimate | -0.79 | -0.83 | -3.43 | -0.82 |
| High Estimate | -0.79 | -0.83 | -3.43 | -0.82 |
| Year Ago EPS | -0.6 | -0.69 | -2.71 | -3.43 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 650k | 670k | 2.7M | 1.8M |
| Low Estimate | 650k | 670k | 2.7M | 1.8M |
| High Estimate | 650k | 670k | 2.7M | 1.8M |
| Year Ago Sales | 606k | 651k | 2.54M | 2.7M |
| Sales Growth (year/est) | 7.30% | 2.90% | 6.30% | -33.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.1 | -1.13 | -1.12 | -0.87 |
| EPS Actual | -0.6 | -0.69 | -0.69 | -0.77 |
| Difference | 0.5 | 0.44 | 0.43 | 0.1 |
| Surprise % | 45.50% | 38.90% | 38.40% | 11.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.79 | -0.83 | -3.43 | -0.82 |
| 7 Days Ago | -0.79 | -0.83 | -3.43 | -0.82 |
| 30 Days Ago | 0 | 0 | -0.64 | -0.93 |
| 60 Days Ago | 0 | 0 | -0.64 | -0.93 |
| 90 Days Ago | 0 | 0 | -0.64 | -0.93 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | XBIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -31.70% | -- | -- | 0.80% |
| Next Qtr. | -20.30% | -- | -- | 9.60% |
| Current Year | -26.60% | -- | -- | 4.50% |
| Next Year | 76.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/16/2023 |
Related Tickers
AKTX Akari Therapeutics, Plc
1.2100
+1.68%
PHIO Phio Pharmaceuticals Corp.
0.6378
-0.58%
VRPX Virpax Pharmaceuticals, Inc.
4.0400
+17.44%
XBIT XBiotech Inc.
7.91
-2.47%
QLGN Qualigen Therapeutics, Inc.
0.3117
+5.45%
PULM Pulmatrix, Inc.
1.9600
-5.31%
BLPH Bellerophon Therapeutics, Inc.
0.0571
+4.77%
INDP Indaptus Therapeutics, Inc.
2.5200
-1.18%
KTTA Pasithea Therapeutics Corp.
7.15
0.00%
CRVS Corvus Pharmaceuticals, Inc.
1.4100
+3.68%